{"pub_date": "2016-04-27T00:00:00Z", "subsection_name": null, "lead_paragraph": "The troubled testing company dazzled the media, but Palo Alto investors were the first to see the potential flaws.", "print_page": "23", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "STROSS", "firstname": "Randall", "role": "reported"}], "original": "By RANDALL STROSS"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/04/27/opinion/27strossWeb/27strossWeb-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/04/27/opinion/27strossWeb/27strossWeb-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 429, "url": "images/2016/04/27/opinion/27strossWeb/27strossWeb-articleLarge-v2.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "429", "xlarge": "images/2016/04/27/opinion/27strossWeb/27strossWeb-articleLarge-v2.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/04/27/opinion/27strossWeb/27strossWeb-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/04/27/opinion/27strossWeb/27strossWeb-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Opinion", "headline": {"content_kicker": "Op-Ed Contributor", "print_headline": "Theranos Isn\u2019t Silicon Valley\u2019s Fault", "main": "Don\u2019t Blame Silicon Valley for Theranos", "kicker": "Op-Ed Contributor"}, "source": "The New York Times", "blog": [], "word_count": "873", "web_url": "http://www.nytimes.com/2016/04/27/opinion/dont-blame-silicon-valley-for-theranos.html", "slideshow_credits": null, "news_desk": "OpEd", "type_of_material": "Op-Ed", "snippet": "The troubled testing company dazzled the media, but Palo Alto investors were the first to see the potential flaws.", "_id": "5720686138f0d82fc1b0ffa4", "abstract": "Op-Ed article by author Randall Stross contradicts those who would portray turmoil surrounding medical diagnostics start-up Theranos as typical case of irresponsible Silicon Valley hype; holds seasoned investors saw early red flags in company's methods but Walgreens, eager like many old-world companies to acquire small innovators, seized chance for lucrative investment.  ", "keywords": [{"rank": "1", "name": "organizations", "value": "Theranos Inc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Venture Capital", "is_major": "Y"}, {"rank": "3", "name": "organizations", "value": "Walgreen Co.", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Tests (Medical)", "is_major": "Y"}, {"rank": "5", "name": "subject", "value": "Blood", "is_major": "Y"}, {"rank": "6", "name": "subject", "value": "Start-ups", "is_major": "N"}, {"rank": "7", "name": "persons", "value": "Holmes, Elizabeth (1984- )", "is_major": "N"}]}